Our objective is to present the pharmacological mechanisms, safety profiles, and regulatory status of prominent approved and unapproved peptides marketed direct to patients, including AOD-9604 (anti-obesity drug 9604), BPC-157 (body protection compound 157), CJC-1295, FS-344 (follistatin-344), GHK-Cu (glycyl-l-histidyl-l-lysine copper), ipamorelin, MOTS-C (mitochondrial ORF of the 12S rRNA type-c), sermorelin, SS-31 (elamipretide), tesamorelin (Egrifta), T4 (thymosin beta-4), and TB-500 (thymosin beta-4 fragment)
Q: Can I use it for all peptides
Direct injectable NAD+ (limited human evidence) Historical IV case reports (O'Holleran 1961) plus pilot pharmacokinetic comparisons (e.g
A 2025 safety study confirmed that IV BPC-157 was well tolerated in healthy adults with no adverse events
"One thing that stood out from the project was the number of people who didn't want to know the results," recalls Behnke